Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy

Prostate

Volumn 71, Issue 14, 2011, Pages 1492-1498

  De Nunzio, Cosimo ^a   Freedland, Stephen J ^b   Miano, Roberto ^c   Trucchi, Alberto ^a   Cantiani, Andrea ^a   Carluccini, Alfonso ^a   Tubaro, Andrea ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Gleason score; metabolic syndrome; needle biopsy; obesity; prostate cancer

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; NEOSTIGMINE;

AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BODY MASS; CANCER PATIENT; CANCER RISK; CHOLESTEROL BLOOD LEVEL; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BIOPSY; BLOOD; BLOOD PRESSURE; CANCER GRADING; COMPLICATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; RISK ASSESSMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOPSY; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL, HDL; DIGITAL RECTAL EXAMINATION; HUMANS; KALLIKREINS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEOPLASM GRADING; NEOSTIGMINE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 80052103055     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21364     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Hsing AW, Sakoda LC, Chua S,. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007; 86: 843-857.
3. Nobes JP, Langley SE, Laing RW,. Metabolic syndrome and prostate cancer: A review. Clin Oncol 2009; 21: 183-191.
4. Beebe-Dimmer JL, Nock NL, Neslund-Dudas C, Rundle A, Bock CH, Tang D, Jankowski M, Rybicki BA,. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 2007; 109: 875-881. (Pubitemid 46333529)
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002; 106 (25): 3143-3421.
6. Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI,. Components of the metabolic syndrome and risk of prostate cancer: The HUNT 2 cohort, Norway. Cancer Causes Control 2009; 20: 1181-1192.
7. Lund HÃ¥heim, L, Wisløff TF, Holme I, Nafstad P,. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 2005; 164: 769-774. (Pubitemid 44522081)
8. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT,. Metabolic syndrome and the risk of prostate cancer in Finnish men: A population-based study. Cancer Epidemiol Biomarkers Prev 2004; 13: 1646-1650. (Pubitemid 39331887)
9. Tande AJ, Platz EA, Folsom AR,. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 2006; 164: 1094-1102. (Pubitemid 44851745)
10. Beebe-Dimmer JL, Nock NL, Neslund-Dudas C, Rundle A, Bock CH, Tang D, Jankowski M, Rybicki BA,. Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology 2009; 74: 185-190.
11. De Nunzio C, Trucchi A, Miano R, Stoppacciaro A, Fattahi H, Cicione A, Tubaro A,. The number of positive cores for hgpin on initial biopsy is associated with prostate cancer on second biopsy. J Urol 2009; 181: 1069-1074.
12. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA,. American Cancer Society Prostate Cancer Advisory Committee. American Cancer Society guideline for the early detection of prostate cancer: Update 2010. CA Cancer J Clin 2010; 60 (2): 70-98.
13. Serfling R, Shulman M, Thompson GL, Xiao Z, Benaim E, Roehrborn CG, Rittmaster R,. Quantifying the impact of prostate volumes, number of biopsy cores and 5-alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modelling. J Urol 2007; 177: 2352-2356. (Pubitemid 46726388)
14. Presti JC Jr, O'Dowd GJ, Miller MC, Mattu R, Veltri RW,. Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: Results of a community multi-practice study. J Urol 2003; 169: 125-129. (Pubitemid 35461569)
15. Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R,. Hypogonadism and metabolic syndrome: Implications for tetstosterone theraphy. J Urol 2006; 174: 827-834.
16. Freedland SJ, Wen J, Wuerstle M, Shah A, Lai D, Moalej B, Atala C, Aronson WJ,. Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology 2008; 72 (5): 1102-1105.
17. Pruthi RS, Swords K, Schultz H, Carson CC 3rd, Wallen EM,. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme. J Urol 2009; 181: 574-577.
18. Buschemeyer WC, Freedland SJ,. Obesity and prostate cancer: Epidemiology and clinical implications. Eur Urol 2007; 52 (2): 331-343. (Pubitemid 46963472)
19. Jayachandran J, Bañez LL, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Freedland SJ,. Obesity as predictor of adverse outcomes across black and white race. Cancer 2009; 11: 5263-5271.
20. Wallström P, Bjartell A, Gullberg B, Olsson H, Wirfält E,. A prospective Swedish study on body size, body composition, diabetes and prostate cancer risk. Br J Cancer 2009; 100: 1799-1805.
21. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C,. Definition of metabolic syndrome: Report of the national heart, lung and blood institute/American heart association conference on scientific issues related to definition. Circulation 2004; 109: 433-438. (Pubitemid 38133916)
22. Jaggers JR, Sui X, Hooker SP, LaMonte MJ, Matthews CE, Hand GA, Blair SN,. Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer 2009; 45 (10): 1831-1838.
23. Smith MR, Lee H, Fallon MA, Nathan DM,. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-224.
24. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. , Effect of Dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-1202.
25. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS,. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 2008; 71: 318-322.